Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Clin Cancer Res. 2020 Nov 10;27(3):852–864. doi: 10.1158/1078-0432.CCR-20-1192

Figure 6. Summary of proposed ACC subtypes.

Figure 6.

(A) Combination of the original and validation cohort showing subtype, score, MYC/TP63 gene expression levels, tumor stage, histology, and primary site. *p<0.05 association with subtype.

(B) Overall survival in combined cohort. Log-rank test.

(C) Multivariate survival analysis using Cox proportional hazards model in the combined cohort accounting for subtype, tumor stage, and tumor histology.

(D) ACC-I is characterized by MYC hyperactivation via Notch or direct amplification, both of which can suppress p63. In absence of these events, p63 drives EGFR or other RTKs to promote proliferation.